Haemonetics Announces Executive Leadership Updates
Haemonetics (NYSE: HAE) announced key executive leadership updates. Frank Chan, Ph.D. will join as Executive Vice President, Chief Operating Officer on April 7, 2025, while Roy Galvin has been appointed Executive Vice President, Chief Commercial Officer with immediate effect.
Chan, bringing over 25 years of medical device and healthcare technology leadership experience, will oversee research and development, regulatory affairs, global manufacturing, and supply chain operations. He joins from Medtronic plc, where he served as President of Acute Care & Monitoring.
Galvin, who joined Haemonetics in 2022 as President, Global Plasma and Blood Center, will now expand his responsibilities to include the Global Hospital business, directing all commercialization initiatives across the company's full product portfolio. He brings over 25 years of experience from Medtronic plc in the Neuroscience and Orthopedic markets.
Haemonetics (NYSE: HAE) ha annunciato aggiornamenti chiave nella leadership esecutiva. Frank Chan, Ph.D. entrerà come Vice Presidente Esecutivo e Direttore Operativo il 7 aprile 2025, mentre Roy Galvin è stato nominato Vice Presidente Esecutivo e Direttore Commerciale con effetto immediato.
Chan, con oltre 25 anni di esperienza nella leadership nel settore dei dispositivi medici e della tecnologia sanitaria, si occuperà della ricerca e sviluppo, delle questioni regolatorie, della produzione globale e delle operazioni della catena di approvvigionamento. Proviene da Medtronic plc, dove ha ricoperto il ruolo di Presidente della Cura Acuta e Monitoraggio.
Galvin, che è entrato in Haemonetics nel 2022 come Presidente del Plasma Globale e del Centro Sangue, espanderà ora le sue responsabilità per includere il business ospedaliero globale, dirigendo tutte le iniziative di commercializzazione dell'intero portafoglio prodotti dell'azienda. Porta con sé oltre 25 anni di esperienza da Medtronic plc nei mercati delle Neuroscienze e Ortopedia.
Haemonetics (NYSE: HAE) anunció actualizaciones clave en el liderazgo ejecutivo. Frank Chan, Ph.D. se unirá como Vicepresidente Ejecutivo y Director de Operaciones el 7 de abril de 2025, mientras que Roy Galvin ha sido nombrado Vicepresidente Ejecutivo y Director Comercial con efecto inmediato.
Chan, que aporta más de 25 años de experiencia en liderazgo en dispositivos médicos y tecnología de la salud, supervisará la investigación y el desarrollo, los asuntos regulatorios, la fabricación global y las operaciones de la cadena de suministro. Se une a la empresa proveniente de Medtronic plc, donde se desempeñó como Presidente de Cuidado Agudo y Monitoreo.
Galvin, quien se unió a Haemonetics en 2022 como Presidente de Plasma Global y Centro de Sangre, ahora ampliará sus responsabilidades para incluir el negocio hospitalario global, dirigiendo todas las iniciativas de comercialización en todo el portafolio de productos de la compañía. Aporta más de 25 años de experiencia de Medtronic plc en los mercados de Neurociencia y Ortopedia.
Haemonetics (NYSE: HAE)는 주요 경영진 리더십 업데이트를 발표했습니다. Frank Chan, Ph.D.는 2025년 4월 7일부터 부사장 겸 COO로 합류하며, Roy Galvin은 즉시 부사장 겸 CCO로 임명되었습니다.
Chan은 의료 기기 및 헬스케어 기술 분야에서 25년 이상의 리더십 경험을 바탕으로 연구 및 개발, 규제 업무, 글로벌 제조 및 공급망 운영을 감독할 것입니다. 그는 Medtronic plc에서 급성 치료 및 모니터링의 사장으로 재직하다가 합류합니다.
Galvin은 2022년 Haemonetics에 글로벌 플라스마 및 혈액 센터의 사장으로 합류했으며, 이제는 글로벌 병원 비즈니스까지 책임을 확대하여 회사의 전체 제품 포트폴리오에 걸친 모든 상업화 이니셔티브를 지휘합니다. 그는 Medtronic plc에서 신경과학 및 정형외과 시장에서 25년 이상의 경험을 가지고 있습니다.
Haemonetics (NYSE: HAE) a annoncé des mises à jour clés concernant la direction exécutive. Frank Chan, Ph.D. rejoindra l'entreprise en tant que Vice-Président Exécutif et Directeur des Opérations le 7 avril 2025, tandis que Roy Galvin a été nommé Vice-Président Exécutif et Directeur Commercial avec effet immédiat.
Chan, qui apporte plus de 25 ans d'expérience en leadership dans les dispositifs médicaux et la technologie de la santé, supervisera la recherche et le développement, les affaires réglementaires, la fabrication mondiale et les opérations de la chaîne d'approvisionnement. Il rejoint l'entreprise après avoir été Président des Soins Aigus et de la Surveillance chez Medtronic plc.
Galvin, qui a rejoint Haemonetics en 2022 en tant que Président du Plasma Global et du Centre de Sang, élargira désormais ses responsabilités pour inclure l'activité hôpital mondiale, dirigeant toutes les initiatives de commercialisation à travers l'ensemble du portefeuille de produits de l'entreprise. Il apporte plus de 25 ans d'expérience de Medtronic plc sur les marchés des neurosciences et de l'orthopédie.
Haemonetics (NYSE: HAE) hat wichtige Updates zur Führungsebene bekannt gegeben. Frank Chan, Ph.D. wird am 7. April 2025 als Executive Vice President und Chief Operating Officer einsteigen, während Roy Galvin mit sofortiger Wirkung zum Executive Vice President und Chief Commercial Officer ernannt wurde.
Chan, der über 25 Jahre Erfahrung in der Führung von Medizintechnik und Gesundheitstechnologie verfügt, wird die Bereiche Forschung und Entwicklung, regulatorische Angelegenheiten, globale Fertigung und Lieferkettenoperationen leiten. Er kommt von Medtronic plc, wo er als Präsident für Akutversorgung und Monitoring tätig war.
Galvin, der 2022 als Präsident für Global Plasma and Blood Center zu Haemonetics kam, wird nun seine Verantwortung auf das globale Krankenhausgeschäft ausweiten und alle Kommerzialisierungsinitiativen für das gesamte Produktportfolio des Unternehmens leiten. Er bringt über 25 Jahre Erfahrung aus Medtronic plc in den Bereichen Neurowissenschaften und Orthopädie mit.
- Strategic leadership strengthening with experienced healthcare technology executives
- Expanded commercial leadership scope under new CCO role
- Addition of seasoned COO with 25+ years industry experience
- None.
Frank Chan joins Haemonetics as Executive Vice President, Chief Operating Officer; Roy Galvin named Executive Vice President, Chief Commercial Officer
As Chief Operating Officer, Chan will direct Haemonetics' research and development as well as regulatory affairs, driving innovation and operational excellence to support the company's growth. He will also oversee Haemonetics' global manufacturing and supply chain operations. He will report to Chris Simon, Haemonetics' President and Chief Executive Officer.
With more than 25 years of experience in medical device and healthcare technology leadership, Chan has successfully delivered innovative solutions to market, expanded patient access with global market development, and led business transformation initiatives across large organizations. He joins Haemonetics from Medtronic plc, where he served as President of Acute Care & Monitoring, overseeing a global portfolio of airway management, patient monitoring, and connected care solutions. Prior to Medtronic, he held roles of increasing responsibility at Covidien plc (acquired by Medtronic) and DePuy Orthapaedics, Inc. (a Johnson & Johnson company).
Galvin joined Haemonetics in 2022 as President, Global Plasma and Blood Center. As Chief Commercial Officer, he will now have responsibility for the company's Global Hospital business as well as Global Plasma and Blood Center, directing all commercialization initiatives to expand the reach and breadth of Haemonetics' full product portfolio. Galvin brings to the role extensive experience in the global healthcare technology field for hospitals and the surgical suite, with over 25 years working at Medtronic plc scaling businesses in the Neuroscience and Orthopedic markets.
"We are executing our long-range plan to achieve exciting growth and build a foundation for sustained success. By strengthening our executive leadership with the addition of Frank Chan and an expanded role for Roy Galvin, we are well-positioned to drive the next phase of our growth," said Chris Simon.
About Haemonetics
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.
Investor Contacts: | ||||
Olga Guyette, Vice President-Investor Relations & Treasury Investor Relations | David Trenk, Manager-Investor Relations | |||
(781) 356-9763 | (203) 733-4987 | |||
Media Contact: | ||||
Josh Gitelson, Senior Director-Global Communications | ||||
(781) 356-9776 | ||||
View original content to download multimedia:https://www.prnewswire.com/news-releases/haemonetics-announces-executive-leadership-updates-302390394.html
SOURCE Haemonetics Corporation
FAQ
When will Frank Chan start as COO at Haemonetics (HAE)?
What are Frank Chan's responsibilities as the new COO of HAE?
What is Roy Galvin's new role at Haemonetics (HAE)?
What was Roy Galvin's previous position at HAE before becoming CCO?
